Akesis Pharmaceuticals

• Home
• About Us
  • Fast Facts
  • Management
  • Board of Directors
  • Scientific Advisory Board
• Pipeline
  • The Diabetes Epidemic
  • Intellectual Property
• Investor Relations
  • Stock Information
  • Akesis Team
  • Press Releases
  • SEC Filings
• Contact Us
  • Contact Us
  • Legal Information

SAN DIEGO, October 31, 2007 -- Akesis Pharmaceuticals, Inc. (OTC/BB: AKES), an emerging diabetes drug-development company, today announced that Jay Lichter, president and chief executive officer, will present at the Rodman and Renshaw Acumen BioFin 9^th Annual Healthcare Conference on Wednesday, November 7, 2007, at 11:10 a.m. Eastern time (8:10 a.m. Pacific time) at the New York Palace Hotel.

Interested investors may gain access to a live audio webcast and slide presentation via the Internet by visiting the Company's Web site at http://www.akesis.com/.  The presentation will be archived on the Web site for 30 days.

About Akesis

Akesis Pharmaceuticals has a pipeline of innovative oral product candidates for the treatment of diabetes and related metabolic disorders.  These product candidates are supported by issued and filed U.S. patents for both prescription and over-the-counter treatments that combine anti-diabetic trace minerals with certain classes of diabetes oral agents.  Akesis' product candidates have demonstrated preliminary evidence of efficacy in lowering and controlling blood glucose levels in patients with Type 2 diabetes.  Blood sugar control via oral drugs represents a market opportunity in the billions of dollars, as reports indicate that approximately 20 million people suffer from diabetes in the United States alone.  More information can be found at http://www.akesis.com/.

###